Synthaverse S.A. (WSE:SVE)

Market Cap	198.41M -31.6%
Revenue (ttm)	48.76M -21.8%
Net Income	-20.99M
EPS	-0.28
Shares Out	76.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,103
Open	2.600
Previous Close	2.610
Day's Range	2.580 - 2.610
52-Week Range	2.580 - 4.245
Beta	-0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 30, 2026

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anti-D 50 and GAMMA anti-D 150, which are human anti-rh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 214
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SVE

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 4, 2026

Data Sources Report a data error